YASUDA Shohei
No ORCID on file
· 18 papers in corpus
· active 1997-1998
Frequent coauthors
- AJITO Keiichi 18
- KURIHARA KENICHI 18
- MIYAJIMA Kaori 18
- OKONOGI TSUNEO 18
- SHINEI Rie 18
- TANABE KIYOSHI 18
- TATSUTA Kuniaki 18
- TABATA Yuji 18
- YAMAMOTO Yasuo 18
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…